Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOUND-MCL: Acalabrutinib + R-CHOP in Previously Untreated Mantle Cell Lymphoma
NCT07029737Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL), sponsored by AstraZeneca. Started Sep 2025; status: recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07029737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07029737.